Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Human Pathology

• Publication date

  2009-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.humpath.2008.09.006PMID 19070887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in Biology and Therapy of Multiple Myeloma

  2013cited by this paper
• Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas

  2008cited by this paper
• Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

  2007cited by this paper
• Review of thalidomide in the treatment of newly diagnosed multiple myeloma

  2007cited by this paper
• Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma

  2007cited by this paper
• Thalidomide and lenalidomide in the treatment of multiple myeloma.

  2006cited by this paper
• Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

  2006cited by this paper
• Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.

  2006cited by this paper
• Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.

  2006cited by this paper
• Molecular pathogenesis and a consequent classification of multiple myeloma.

  2005cited by this paper
• Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.

  2005influential reference
• Early genetic events provide the basis for a clinical classification of multiple myeloma.

  2005cited by this paper
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

  2005influential reference
• Genetics and Cytogenetics of Multiple Myeloma

  2004influential reference
• Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.

  2004cited by this paper
• The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

  2004cited by this paper
• p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

  2004cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.

  2003cited by this paper
• Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

  2003cited by this paper
• Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

  2003cited by this paper
• Clinical and biologic implications of recurrent genomic aberrations in myeloma.

  2003cited by this paper
• Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.

  2003cited by this paper
• Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

  2002cited by this paper
• Chromosome translocations in multiple myeloma

  2001cited by this paper
• Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance

  2000cited by this paper
• Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

  2000cited by this paper
• Cyclin D1 expression in patients with multiple myeloma.

  2000cited by this paper
• Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

  1998cited by this paper
• Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

  1997cited by this paper

• Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya

  2023cites this paper
• The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis

  2022cites this paper
• The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients

  2017cites this paper
• Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.

  2014influential citation
• A Case of Extramedullary Plasmacytoma Arising from Maxillary Sinus

  2013cites this paper
• Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review

  2013influential citation
• Chapter 8The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients

  2012cites this paper
• Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

  2012cites this paper
• p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.

  2012cites this paper
• Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.

  2009cites this paper
• Ekspresija ciklina D 1 u koštanoj srži pacijenata s multiplim mijelomom prije i poslije terapije bortezomibom Expression of cyclin D 1 in bone marrow of multiple myeloma patients before and after bortezomib treatment

  year unknowncites this paper
• The Application of Clinical Genetics Dovepress Genetic and Molecular Mechanisms in Multiple Myeloma: a Route to Better Understand Disease Pathogenesis and Heterogeneity

  year unknowncites this paper